Entrectinib, which inhibits ROS1, ALK, three TRKs, and TRK-fusion tyrosine kinases, has shown an RR of 57% (31 of 54 patients) [107], and is approved by the FDA for NTRK gene fusion-positive solid tumors and ROS1-positive non-small cell lung cancer. Here, ROS1 is linked to non-small cell lung carcinoma.